Blue Therapeutics announces Series A raise
Unveiling disruptive IND stage receptor-interactomicsTM platform and pipeline
News provided by
Share this article
Share this article
WALTHAM, Mass., April 30, 2021 /PRNewswire/ Blue Therapeutics is a Boston based drug discovery and development company. The lead asset BLUE-181 is approaching IND and has successfully provided the proof of concept and the blueprint for the R2i platform. Based on the concept of receptor-interactomics
TM the R2i platform opens up a new dimension for drug discovery. Blue has developed an early pipeline of disruptive opportunities which demonstrate the broad applicability of the technology across receptor classes and diseases. To leverage the full potential of the platform and enter the clinical phase with BLUE-181 the company is now opening a window into their science and business model in the context of their Series A raise.
MedCity News
Read about new developments from Seven Bridges, Blue Therapeutics, Outcomes4Me and more.
Shares0
Seven Bridges this week announced the close of the first $15 million of a planned $30 million Series C round from a new life sciences investor. This investment will support the company in its mission to accelerate scientific discovery and speed the path from raw experimental data to new treatments and diagnostics.
“Multi-omics tools are fast-becoming ubiquitous drivers of scientific innovation. As the industry’s leading enterprise bioinformatics ecosystem provider, Seven Bridges provides its clients the ability to facilitate discovery by helping researchers generate meaningful insights from vast quantities of data,” said William Moss, chief executive officer of Seven Bridges. “This new investment is a recognition of the leading role Seven Bridges plays in the future of biomedical innovation and will help us continue to innovate and scale our organization to serv